Literature DB >> 6606041

In vivo antinuclear antibodies (ANA) in biopsies of normal skin: diagnostic significance and relation to serum ANA.

C G Kallenberg, M C de Jong, T M Walstra, S Kardaun, T H The.   

Abstract

Epidermal nuclear Ig deposition (in vivo ANA) was observed in 54 out of 1,717 skin biopsy specimens routinely examined by immunofluorescence. Patterns were speckled (26), homogeneous (24), or nucleolar (3). The speckled pattern was sensitive (94%) but less specific (58%) for mixed connective tissue disease. The homogeneous pattern, found in SLE and scleroderma, was neither sensitive nor specific for those diseases. The nucleolar pattern was infrequently observed in scleroderma. Patterns of in vivo ANA and serum ANA did not correspond in 24% of patients. In vivo ANA were restricted to IgG class; serum ANA in 78% of patients were also of IgM class and in 37% of IgA class. The discrepancies between in vivo and serum ANA suggest that in vivo ANA is a true in vivo phenomenon.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606041

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

1.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Antinuclear antibody (ANA) substrates and quantification techniques.

Authors:  C G Kallenberg; P C Limburg
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

3.  In vivo antinuclear antibody of the skin: diagnostic significance and association with selective antinuclear antibodies.

Authors:  P J Velthuis; L Kater; I van der Tweel; F G Meyling; R H Derksen; R J Hené; J A van Geutselaar; H Baart de la Faille
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

4.  Quantitation of antibodies to nucleoribonucleoprotein by ELISA: relation between antibody levels and disease activity in patients with connective tissue disease.

Authors:  P M Houtman; C G Kallenberg; P C Limburg; M G Huitema; M H van Rijswijk; T H The
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.